Therefore, we believe that this case series highlights the potential of [18F]PI-2620 to more easily overcome these limitations than earlier tracers, offering a foundation for future research to explore tau deposition in DS-AD with greater accuracy and reliability. This evidence concerns the gene MAPT and Alzheimer disease.